Composite

Part:BBa_K1714001

Designed by: Masaya Mitsumoto   Group: iGEM15_HokkaidoU_Japan   (2015-09-10)
Revision as of 18:26, 18 September 2015 by Tamaro (Talk | contribs)

pLac-RBS B0034-ABF-2-double terminator

Hokkaidou_co-expression_Fig.5.png


This part will be finally introduced upstream of BBa_K1714004 (PBAD-B0034-BLA-dT on 1C3) and expressed as AMPs in Co-expression system. In this page, I described the result of the activity assay of ABF-2.

Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    INCOMPATIBLE WITH RFC[25]
    Illegal AgeI site found at 321
  • 1000
    COMPATIBLE WITH RFC[1000]



In this page, I described the result of the activity assay of ABF-2.

We transformed it into E. coli (in this case, we used DH5α) and compared the growth curve between samples induced or not. Activity test for ABF-2 and thanatin →Comparing growth curve between the samples one is induced by IPTG and the other is not induced.

  1. Diluting the bacterial culture which is enough pre-cultured by 0.1 OD600 (Optical Density in λ=600nm) in 2 mL LBC.(Lysogeny Broth liquid culture including chloramphenicol)
  2. Adding 2 µL of IPTG into one and DW into the other.
  3. Measuring OD600 of these samples once in an hour.

As a result, we got the graph of growth curve of DH5α and shown on below as Chart1.

Hokkaidou_co-expresion_Fig.4.png

Fig. 8. The growth curve of E. coli including BBa_K1714001 with IPTG or not.

As you can see, we can’t say that ABF-2 in BBa_K1714001 has correct antimicrobial activity.

[edit]
Categories
Parameters
None